Related by context. All words. (Click for frequent words.) 74 mcg kg 74 mg/m2 74 #mg/kg [002] 73 mg 73 mcg 72 μg 71 μg kg 70 mg m 69 mg kg dose 69 mg d 67 mg QD 67 ug kg 67 mg dose 67 n = 66 mg BID 66 mcg mL 66 placebo 66 #.#mg/kg [002] 66 #mg/m# [002] 65 #mg/m# [001] 65 intramuscularly 64 4mg/kg 64 mg/m2/day 64 lopinavir r 64 dexamethasone 64 μmol L 63 mcg dose 62 #mg [003] 62 mg m² 62 mg kg bw 62 log# 62 plus ribavirin 62 microg 62 3mg 62 8mg/kg 62 #mg/day [001] 61 ng mL 61 administered subcutaneously 61 #mg QD [002] 61 plasma concentrations 61 placebo p = 61 ng ml 61 mCi kg 61 g dL 61 FOLFOX 61 #.#mg [004] 61 kilogram mg kg 61 μg mL 61 Peg IFN 61 Cmax 61 piperacillin tazobactam 60 mg orally 60 mg TID 60 #μg [001] 60 peginterferon alfa 2a 60 mcg BID 60 docetaxel 60 LPV r 60 ug mL 60 mitoxantrone 60 #.#mg/kg [001] 60 placebo p 60 μg dose 60 Q2W 60 3mg/kg 60 timepoint 60 g dl 59 NOAEL 59 lispro 59 #mg BID [003] 59 #mg/kg [001] 59 CIMZIA TM 59 lopinavir r arm 59 alanine aminotransferase 59 #mg [001] 59 saline placebo 59 achieved ACR# 59 nmol 59 pg mL 59 median PFS 59 pg ml 59 1mg 59 subcutaneous injections 59 plus dexamethasone 59 atazanavir ritonavir 59 timepoints 59 mg mL 59 oral allopurinol 59 #mg/day [002] 59 subcutaneously 59 8mg 58 mcg albinterferon alfa 2b 58 mg ustekinumab 58 mg kg hr 58 mg ml 58 fluorouracil 58 microgram kg 58 mcg Albuferon 58 μg L 58 aspartate aminotransferase 58 1mg/kg 58 mg subcutaneously 58 mg/m2 dose 58 mg kg IV 58 #mg BID [001] 58 q#h 58 oral prednisone 58 mcg doses 58 kg -1 58 p = #.# [002] 58 ascending doses 58 IU mL 58 mmol L 58 achieved PASI 58 mg doses 58 #μg [002] 58 log# copies mL 58 #.#mg/dL 58 PREZISTA ritonavir 58 lanthanum carbonate 58 mM 58 intravitreal injection 58 intravenous bolus 58 peg IFN 58 nM 57 mg dosed 57 uM 57 #.#g/day 57 p = #.# [004] 57 peginterferon alfa 2b 57 ascending dose 57 mg tid 57 QD dosing 57 dosed 57 P = .# 57 pegylated interferon alfa 2a 57 5-FU/LV 57 mg qd 57 hypokalemia 57 mL 57 #mg BID [002] 57 nmol L 57 monotherapy 57 evaluable 57 p = 57 hours postdose 57 serum concentrations 57 ribavirin RBV 57 #mg [002] 57 evaluable patients 57 plasma HCV RNA 57 amoxicillin clavulanate 57 mg/m2 IV 57 dosing cohort 57 plus medroxyprogesterone acetate 57 certolizumab 57 dosed orally 57 chlorambucil 57 2mg 57 PREZISTA r 57 intravenous dosing 56 gemcitabine 56 ug ml 56 mCi m 2 56 adalimumab 56 mg eq 56 serum phosphorus 56 creatinine ratio 56 REBETOL 56 kBq kg 56 milligrams mg 56 hypomagnesemia 56 μg ml 56 mu g 56 administered orally 56 mg/# hr 56 QTcF 56 insulin detemir 56 placebo capsules 56 daunorubicin 56 mEq 56 mL kg 56 #ug [001] 56 achieved statistical significance 56 confidence interval CI 56 μM 56 LANTUS R 56 subcutaneous dose 56 progression TTP 56 randomized #:# 56 tipranavir r 56 pmol L 56 #mcg [003] 56 doxorubicin cyclophosphamide 56 μg g 56 ng dL 56 mcg QD 56 abacavir lamivudine 56 bolus injection 56 ropivacaine 56 IU ml 56 plasma uric acid 56 MADRS score 56 dosing cohorts 56 mIU mL 56 % Confidence Interval 56 fluorouracil leucovorin 56 titrated 56 budesonide pMDI 56 etanercept 56 mEq L 56 FEV1 56 5mg/kg 56 FOLFOX4 56 bupivacaine 56 mg RDEA# 56 ng dl 56 plasma glucose 56 etoposide 56 dosing interval 56 6mg 56 interferon alfa 2b 56 pmol liter 56 μg doses 56 #mg doses [002] 56 μg d 56 ≥ 56 randomized 55 mmol kg 55 dose cohort 55 GnRH agonist 55 mCi 55 comparator arm 55 idarubicin 55 posaconazole 55 pegylated interferon 55 LEXIVA r 55 ACR# response 55 lumbar spine BMD 55 desvenlafaxine succinate 55 q8h 55 inactive placebo 55 log# IU mL 55 dosing 55 nab paclitaxel 55 DLTs 55 log# reduction 55 rFSH 55 dose colchicine 55 mg/# hours 55 baseline HbA1c 55 mg dL 55 deferoxamine 55 dacarbazine 55 active comparator 55 Median survival 55 Acetate Rectal Suppositories 55 peginterferon alfa 2a #KD 55 plus methotrexate 55 mg dosed twice 55 FOLFIRI 55 epoetin alfa 55 APTIVUS r 55 primary efficacy endpoint 55 continuous intravenous infusion 55 MBq 55 adjunctive placebo 55 mol L 55 flutamide 55 primary endpoint 55 copies mL 55 degarelix 55 MIC# [001] 55 infliximab 55 statistically significant improvement 55 cyclophosphamide 55 octreotide LAR 55 % CI #.#-#.# [002] 55 mg/m2 administered 55 adefovir 55 Pegasys ® 55 q# 55 intermittent dosing 55 interferon alfa 2a 55 subcutaneously administered 55 ACTEMRA TM 55 fosamprenavir 55 IFN alfa 55 undetectable HCV RNA 54 antibody titers 54 subcutaneous SC 54 microgram 54 amprenavir 54 ml kg 54 Elitek 54 bevacizumab 54 oxycodone CR 54 ritonavir boosted 54 inhalations twice 54 ABC/3TC 54 rhEPO 54 doxorubicin docetaxel 54 blood Phe 54 #mg QD [001] 54 mU liter 54 mg calcium 54 micrograms mcg 54 #mg dose [003] 54 isoproterenol 54 VELCADE melphalan 54 FOLFIRI alone 54 pyrazinamide 54 ketorolac 54 NPH insulin 54 REYATAZ r arm 54 #.#mg [003] 54 tiotropium 54 unfractionated heparin 54 ALVESCO 54 relapsed MM 54 biochemical relapse 54 corticosteroid dose 54 5FU 54 mg Lucentis 54 PaO 2 54 mg simvastatin 54 nmol liter 54 clodronate 54 docetaxel chemotherapy 54 1mg 2mg 54 μg l 54 oral rivaroxaban 54 mg/# h 54 salmeterol fluticasone propionate 54 pegaptanib 54 Tarceva TM 54 deferasirox 54 safety tolerability pharmacokinetics 54 #-#,# mg 54 gastric pH 54 subcutaneous doses 54 REYATAZ r 54 rapid virologic response 54 mcg ml 54 nelfinavir 54 CANCIDAS 54 azathioprine 54 #ug [002] 54 beclomethasone dipropionate 54 ibandronate 54 serum phosphate levels 54 fluticasone 54 #mg dose [001] 54 creatinine clearance 54 sUA 54 statistically significant p = 54 bronchodilation 54 mmol l 54 pegylated liposomal doxorubicin 54 statistically significant reduction 54 DOXIL 54 tinzaparin 54 estramustine 54 fluticasone salmeterol 54 dose limiting toxicities 54 carboplatin paclitaxel 54 tolterodine ER 54 tapentadol ER 54 peginterferon 54 Locteron administered 54 intramuscular dose 54 CsA 53 interquartile range 53 carboplatin 53 mcg kg min 53 severe neutropenia 53 rizatriptan 53 Gy 53 rotigotine 53 FOLFOX4 alone 53 induction regimen 53 p = NS 53 -#.# mg dL [002] 53 cGy 53 dexamethasone Decadron 53 free survival PFS 53 HCV RNA 53 mg administered orally 53 steroid dexamethasone 53 ± 53 patients evaluable 53 dose escalation 53 4mg 53 leuprorelin 53 fluticasone furoate 53 telaprevir dosed 53 alanine aminotransferase ALT 53 -#.# ± [002] 53 ULORIC 53 non inferiority 53 ritonavir boosted atazanavir 53 % CI #.#-#.# [003] 53 IV bolus 53 LAB GHRH 53 miconazole 53 SCIg 53 aminotransferase levels 53 dose cohorts 53 timolol 53 insulin glargine 53 cisplatin gemcitabine 53 -#.# log# 53 tacrolimus ointment 53 febrile neutropenia 53 randomized #:#:# 53 IFN α 53 intravenous dose 53 serum potassium 53 evaluable subjects 53 pegylated interferon alfa 2b 53 adjunctive ABILIFY 53 injected subcutaneously 53 intravenous doses 53 G CSF 53 mg kg intravenously 53 events AEs 53 receiving VICTRELIS 53 EMEND 53 telaprevir dosing 53 beta2 agonist 53 adriamycin 53 AUC0 53 mg/# mg [002] 53 interferon alfa 53 ganciclovir 53 fasting plasma glucose FPG 53 virologic failure 53 irbesartan 53 Psoriasis Area 53 pemetrexed 53 mesalamine 53 HBeAg seroconversion 53 mg q8h 53 intradermal injections 53 PEG Intron ® 53 intravenous infusion 53 micromoles 53 statistically significant p 53 lenalidomide 53 bolus dose 53 transaminase 53 alfa 2a 53 FOLPI regimen 53 SVR# 53 mesalamine granules 53 cyclophosphamide methotrexate 53 systemic absorption 53 dosing intervals 53 serum uric acid 53 COPEGUS 53 pruritis 53 bendamustine 53 serum HBV DNA 53 CCyR 52 azacitidine 52 melphalan 52 Adverse events 52 Gy fractions 52 dose regimens 52 metastatic GIST 52 milligram doses 52 mg uk 52 ìg 52 pegIFN 52 fluoropyrimidine 52 triamcinolone 52 thrombocytopenia 52 betamethasone 52 tenofovir emtricitabine 52 amphotericin B 52 dihydrochloride 52 inhaled fluticasone 52 PSA nadir 52 fumarate 52 LEXIVA 52 STELARA 52 budesonide 52 serum IGF 52 definite stent thrombosis 52 prucalopride 52 pharmacokinetics PK 52 plasma glucose levels 52 hematologic toxicity 52 virologic response 52 TDF FTC 52 dose cytarabine 52 ceftriaxone 52 aPTT 52 granisetron 52 #mg doses [001] 52 IOP lowering 52 9mg 52 MAS XR 52 lactulose 52 HBeAg positive 52 CI -#.# 52 placebo dexamethasone 52 Pharmacokinetic parameters 52 zonisamide SR 52 dosage regimens 52 insulin lispro 52 ertapenem 52 lumbar spine bone 52 azacytidine 52 aminotransferase elevations greater 52 KOMBIGLYZE XR 52 vinorelbine 52 ONGLYZA 52 tamsulosin 52 hypophosphatemia 52 salmeterol fluticasone 52 mg Androxal 52 intramuscular 52 FOSRENOL ® 52 placebo intravenously 52 subcutaneous enoxaparin 52 EUFLEXXA R 52 bortezomib 52 QTc 52 5 fluorouracil 52 postdose 52 OADs 52 postoperatively 52 vancomycin 52 refractory NSCLC 52 confidence interval #.#-#.# 52 aspartate aminotransferase AST 52 pg g 52 decitabine 52 milligram 52 plus MTX 52 prespecified 52 lanreotide 52 imipenem 52 pharmacokinetic parameters 52 darbepoetin alfa 52 topotecan 52 HBeAg negative patients 52 Omacetaxine mepesuccinate 52 PRADAXA #mg 52 milligrams 52 Apidra ® 52 mitomycin 52 detemir 52 secondary endpoints 52 dose titration 52 discontinuations due 52 lamivudine 52 lactate dehydrogenase 52 laxation 52 intravesical 52 demonstrated statistically significant 52 glulisine 52 ACTH 52 ug L 52 low dose dexamethasone 52 Primary endpoints 52 tacrolimus 52 intraperitoneal injection 52 efavirenz EFV 52 IIIa inhibitor 52 #/#.# mcg 52 antiandrogen 52 hour bronchodilation 52 sunitinib 52 Capecitabine 52 g l 52 BEACOPP 52 fluticasone propionate 52 CR CRu 52 mL/min/#.# m2 52 quetiapine 52 oxycodone IR 52 highly emetogenic 52 certolizumab pegol 52 mg kg Hematide 52 plus gemcitabine 52 seroprotection 52 RECIST criteria 52 Taxotere R 52 % CI #.#-#.# [006] 52 systemic corticosteroid 52 cfu 52 Folfox 52 nasopharyngitis 52 mapatumumab 52 PEG IFN 52 levofloxacin 52 Median PFS 52 pegylated interferon alpha 52 pegylated interferon alfa 52 Median progression 52 postmenopausal osteoporotic women 52 BARACLUDE ® 52 tirofiban 52 mg subcutaneous injection 52 PegIFN 51 micromolar 51 RECIST Response Evaluation Criteria 51 PEGASYS ® 51 dalteparin 51 Secondary endpoints included 51 nonfatal MI 51 hypercalcemia 51 goserelin 51 mg BID dose 51 formoterol fumarate 51 propionate 51 5mg 51 partial remissions 51 μg dL 51 oral antidiabetic medication 51 mmol 51 placebo controlled 51 daily Infergen 51 μg liter 51 COZAAR 51 fluoxetine 51 nicardipine 51 doripenem 51 tiotropium bromide 51 intra articular injection 51 lopinavir ritonavir 51 mL min 51 peg interferon 51 placebo PBO 51 #mg #mg #mg [003] 51 micrograms mL 51 GHRH 51 Ceplene/IL-2 51 temsirolimus 51 mcg linaclotide 51 vitamin D2 51 biologic DMARD 51 ARCOXIA 51 ara C 51 ARIKACE 51 Free Survival PFS 51 nadroparin 51 mg kg REMICADE 51 ATACAND 51 valacyclovir 51 glucuronide 51 min -1 51 mIU L 51 insulin glulisine 51 splenectomized patients 51 patients receiving ERBITUX 51 SCH # 51 mg l 51 statin monotherapy 51 #mg dose [002] 51 ribavirin 51 Taxotere ® 51 dose dexamethasone 51 statistical significance p 51 x ULN 51 medroxyprogesterone acetate 51 serum creatinine 51 potent CYP#A# inhibitors 51 methotrexate 51 retapamulin 51 iobenguane 51 tolerability 51 alkaline phosphatase 51 Dose escalation 51 urinary N telopeptide 51 Secondary endpoints include 51 povidone iodine 51 epoetin alpha 51 pomalidomide 51 tolerated dose MTD 51 norethindrone 51 diuretic chlorthalidone 51 estradiol 51 plus prednisone 51 weekly subcutaneous injections 51 ORENCIA 51 urinary excretion 51 plus prednisone prednisolone 51 BUPHENYL R sodium phenylbutyrate 51 oral levofloxacin 51 % CI #.#-#.# [007] 51 TAXOTERE R 51 Engerix B 51 pimecrolimus cream 51 umol L 51 neostigmine 51 LVEF 51 intraperitoneal 51 Pharmacokinetics PK 51 osmolality 51 pyrimidine nucleoside analog 51 mean baseline HbA1c 51 leukopenia 51 APRISO 51 microbiological eradication 51 Moli# 51 tartrate 51 intra muscular 51 LB# [003] 51 serum albumin 51 p ≤ 51 CrCl 51 serum testosterone 51 cis retinoic acid 51 apremilast 51 secondary endpoint 51 indinavir 51 pharmacokinetics 51 cisplatin vinorelbine 51 plus GP IIb 51 mU 51 -#.# log# copies mL 51 ceftazidime 51 dapagliflozin plus 51 Mg Uk 51 saline injections 51 Cream USP 1 51 adrenocorticotropic hormone ACTH 51 HBeAg positive patients 51 serum cortisol 51 ergocalciferol 51 mg kg cohorts 51 GEMZAR 51 weekly intravenous infusions 51 mg p = 51 titrated glipizide 51 intravenous infusions 51 clotrimazole 51 febuxostat 51 Solid Tumors criteria 51 HIV RNA 51 clinically meaningful improvement 51 mU L 51 postop 51 mL/min/#.# m 2 51 sitagliptin 51 mIU ml 51 nitazoxanide 51 PROCTOCORT ® Suppository Hydrocortisone 51 FOLPI 51 transaminases 51 plus COPEGUS 51 mg canada 51 SGPT 51 daily subcutaneous injections 51 serum urate 51 alfa 2b 51 insulin degludec 51 hemoglobin concentration 51 REVLIMID lenalidomide 51 cisplatin 51 mg dl 51 capecitabine 51 tobramycin 51 imetelstat 51 FOLFOX6 51 #.#/#.# mmHg [001] 51 CHOP chemotherapy 51 transaminase elevations 51 ALT normalization 51 streptozotocin 51 hyperphenylalaninemia HPA due 51 randomization 51 undetectable HBV DNA 51 remifentanil 51 acromegalic patients 51 serum leptin 51 idraparinux 51 TMC# [001] 51 bosentan 51 TORISEL 51 mg Proellex 51 receiving INTRON 51 dose dependently 51 sirolimus 51 pegylated alpha interferon 51 dosing regimen 51 acute gout flares 51 plasma urate 51 viral kinetics 50 methylprednisolone 50 melphalan prednisone 50 mycophenolate mofetil 50 inhaled budesonide 50 ritonavir boosted lopinavir 50 urate lowering 50 PASI scores 50 VAPRISOL 50 5 FU 50 FFNS 50 glargine 50 caspofungin 50 primary hypercholesterolemia 50 kGy 50 p = #.# [003] 50 gastrointestinal perforation 50 CIMZIA R 50 noninferiority 50 PREZISTA r arm 50 palonosetron 50 Creatinine 50 diabetic rats 50 paclitaxel 50 dose escalation trial 50 dose proportionality 50 MeHg 50 vitamin B# folic acid 50 neurologic progression 50 subcutaneously injected 50 prospectively defined 50 mCRC patients 50 plus glycoprotein IIb 50 BUPHENYL 50 receiving highly emetogenic 50 azathioprine monotherapy 50 zolmitriptan 50 PegIFN RBV 50 solifenacin 50 HbA 1c levels 50 inert placebo 50 alteplase 50 HCV RESPOND 2 50 CIMZIA ™ 50 oral olanzapine 50 low dose cytarabine 50 Hazard Ratio HR 50 dosing regimens 50 p = .# [002] 50 ULN 50 dasatinib 50 concentration Cmax 50 BENICAR HCT 50 mmHg 50 severe renal impairment 50 intravenous bolus injection 50 otamixaban 50 FluCAM 50 intravenous REOLYSIN 50 urate lowering therapy 50 pretreatment baseline 50 disease progression 50 prednisone prednisolone plus 50 ALT elevations 50 ancrod 50 intravenously administered 50 PEG Interferon alfa 50 pharmacokinetic profile 50 subcutaneous injection 50 APTIVUS 50 LIALDA 50 highest tertile 50 PEGylated anti 50 microgram doses 50 mg iv peramivir 50 ß carotene 50 peginterferon alpha 2a 50 ZOMIG Nasal Spray 50 Monotherapy 50 Flu Cy 50 arbaclofen 50 thromboembolic events 50 ARIXTRA 50 PEGINTRON 50 budesonide formoterol 50 serum phosphate 50 normal ULN 50 neutrophil counts 50 microgram mcg 50 Response Evaluation Criteria 50 TMC# r 50 MIRCERA 50 MCyR 50 mucosal healing 50 ug dose 50 elevated ALT 50 darunavir ritonavir 50 mg kg ip 50 mitomycin C 50 Traficet EN 50 μmol 50 balsalazide 50 serum sodium 50 generalized edema 50 mRCC 50 hemoglobin A1c HbA1c 50 follitropin beta 50 FOSRENOL R 50 gemcitabine cisplatin 50 randomized placebo controlled 50 adefovir treated 50 Pegasys plus Copegus 50 NNRTI resistance 50 CR nPR 50 biphasic insulin aspart 50 NovoLog ® Mix 50 alpha 2a 50 pmol 50 Serum creatinine 50 median survivals 50 corrected QT interval 50 plasma pharmacokinetics 50 baseline A1C 50 ferrous sulfate 50 DAS# remission 50 darunavir r 50 suppressive therapy 50 endoscopic remission 50 esomeprazole 50 doxorubicin 50 APIDRA R 50 injected intramuscularly 50 ribavirin therapy 50 remission induction 50 6 mercaptopurine 50 plasma folate 50 linezolid 50 CI = 50 GSK# [001] 50 serum TSH 50 tolvaptan 50 copies ml 50 maximally tolerated dose 50 RGT arm 50 oral ribavirin 50 Contrave# 50 EDSS score 50 ethambutol 50 mcg dL 50 virologic 50 alkylating agent 50 HCV genotype 50 tobramycin inhalation solution 50 #ng/ml 50 non splenectomized 50 INVEGA ® 50 Fludara 50 octagam ® 50 IXEMPRA 50 valopicitabine 50 mm3 50 blood phenylalanine Phe 50 dose regimen 50 HbA1c levels 50 mcg kg REBETOL 50 CTA# Injection 50 hemoglobin Hb 50 #mg q8h 50 REMICADE ® 50 treatment naive genotype 50 circulating IGF 50 serum HCV RNA 50 zoledronic acid 50 ferric citrate 50 glucocorticoid 50 inflammatory lesions 50 Durezol 50 serum ALT 50 triacylglycerol 50 iodixanol 50 systemic corticosteroids 50 rhGH 50 terfenadine 50 abciximab 50 seroprotective 50 paclitaxel chemotherapy 50 PASI 50 QT QTc 50 voriconazole 50 gadobutrol 50 mg q#h 50 virologic breakthrough 50 NOXAFIL Oral Suspension 50 Lucentis monotherapy 50 IIIa inhibitors 50 octreotide 50 oral prednisolone 50 undetectable viral 50 Peginterferon Alfa 2a 50 QbG# 50 albinterferon alfa 2b 50 mg FV 50 Index CDAI 50 CIMZIA TM certolizumab pegol 50 #Gy 50 cefazolin 50 complete cytogenetic 49 relapsed CLL